Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
| Autor: | Daniele Generali, G Allevi, V Zanoni, S Bonardi, Mario Martinotti, Alfredo Berruti, Letizia Bazzola, F Gussago, Alberto Bottini, Carla Strina, Roberto Giardini, Daniele Andreis, Adrian L. Harris, Sergio Aguggini, Manuela Milani, Chiara Foroni, Stephen B. Fox, Mariarosa Cappelletti |
|---|---|
| Přispěvatelé: | Allevi, G., Strina, C., Andreis, D., Zanoni, V., Bazzola, L., Bonardi, S., Foroni, C., Milani, M., Cappelletti, M. R., Gussago, F., Aguggini, S., Giardini, R., Martinotti, M., Fox, S. B., Harris, A. L., Bottini, A., Berruti, A., Generali, Daniele |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Cancer Research letrozole medicine.medical_treatment Cohort Studies Antineoplastic Agent Receptors 80 and over Neoadjuvant therapy Adjuvant Progesterone Aged 80 and over Aromatase Inhibitors Letrozole Neoadjuvant Therapy Progesterone Receptor Positive Receptors Estrogen Chemotherapy Adjuvant Cohort Female Receptors Progesterone Nitrile Breast Neoplasm medicine.drug Cohort study Human medicine.medical_specialty Antineoplastic Agents Breast Neoplasms Aged Drug Administration Schedule Humans Ki-67 Antigen Nitriles Triazoles Breast cancer Internal medicine Progesterone receptor medicine Chemotherapy Aromatase Inhibitor Gynecology business.industry neoadjuvant medicine.disease Estrogen Clinical trial Clinical Study pathological complete response Triazole Cohort Studie business |
| Zdroj: | British Journal of Cancer |
| Popis: | Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution study comprised 120 oestrogen receptor (ER)-positive postmenopausal women with primary breast cancer (clinical stage ≥T2, N0-1), from three sequential cohorts (cohort A of 40, cohort B of 40 and cohort C of 40 patients, respectively) based on different duration of the neoadjuvant letrozole. Biological markers such as ER, progesterone receptor, HER2 and Ki-67 expression were tested at diagnosis and at definitive surgery.Results:A total of 89 patients (75.4%) achieved an objective response with 44 (37.3%) clinical CRs and 45 (38.1%) partial responses. The clinical CRs were significantly observed in cohort C (23 out of 40 patients, 57.5%) and B (16 out of 38 patients, 42.1%) compared with cohort A (5 out of 40 patients, 12.5%) (P-value for trend |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|